1064 related articles for article (PubMed ID: 33159022)
41. An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma.
Xu RY; Ding Z; Zhao Q; Ke TY; Chen S; Wang XY; Wang YY; Sheng MF; Wang W; Long N; Shen YX; Xu YZ; Shao W
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456475
[TBL] [Abstract][Full Text] [Related]
42. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
43. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
44. The Comprehensive Analysis of N6-Methyadenosine Writer METTL3 and METTL14 in Gastric Cancer.
Ge Y; Zhang Y; Yang S; Liu T; Zhang T; Feng Y; Wang C; Liang G
J Oncol; 2023; 2023():9822995. PubMed ID: 36866236
[TBL] [Abstract][Full Text] [Related]
45. XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
Wang J; Fan P; Shen P; Fan C; Zhao P; Yao Shen ; Dong K; Ling R; Chen S; Zhang J
Cancer Lett; 2024 Aug; 596():216846. PubMed ID: 38582397
[TBL] [Abstract][Full Text] [Related]
46. The Distinct Function and Localization of METTL3/METTL14 and METTL16 Enzymes in Cardiomyocytes.
Arcidiacono OA; Krejčí J; Bártová E
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143367
[TBL] [Abstract][Full Text] [Related]
47. METTL16 exerts an m
Su R; Dong L; Li Y; Gao M; He PC; Liu W; Wei J; Zhao Z; Gao L; Han L; Deng X; Li C; Prince E; Tan B; Qing Y; Qin X; Shen C; Xue M; Zhou K; Chen Z; Xue J; Li W; Qin H; Wu X; Sun M; Nam Y; Chen CW; Huang W; Horne D; Rosen ST; He C; Chen J
Nat Cell Biol; 2022 Feb; 24(2):205-216. PubMed ID: 35145225
[TBL] [Abstract][Full Text] [Related]
48. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N
Ma JZ; Yang F; Zhou CC; Liu F; Yuan JH; Wang F; Wang TT; Xu QG; Zhou WP; Sun SH
Hepatology; 2017 Feb; 65(2):529-543. PubMed ID: 27774652
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.
Fan Z; Yang G; Zhang W; Liu Q; Liu G; Liu P; Xu L; Wang J; Yan Z; Han H; Liu R; Shu M
J Cell Mol Med; 2021 Nov; 25(21):10197-10212. PubMed ID: 34609072
[TBL] [Abstract][Full Text] [Related]
50. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex.
Wang X; Feng J; Xue Y; Guan Z; Zhang D; Liu Z; Gong Z; Wang Q; Huang J; Tang C; Zou T; Yin P
Nature; 2016 Jun; 534(7608):575-8. PubMed ID: 27281194
[TBL] [Abstract][Full Text] [Related]
51. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.
Chen CJ; Huang JY; Huang JQ; Deng JY; Shangguan XH; Chen AZ; Chen LT; Wu WH
Cell Cycle; 2023 Apr; 22(8):986-1004. PubMed ID: 36762777
[TBL] [Abstract][Full Text] [Related]
52. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Xu J; Chen Q; Tian K; Liang R; Chen T; Gong A; Mathy NW; Yu T; Chen X
Oncol Rep; 2020 Sep; 44(3):973-986. PubMed ID: 32705223
[TBL] [Abstract][Full Text] [Related]
53. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m
Liu L; Wu Y; Li Q; Liang J; He Q; Zhao L; Chen J; Cheng M; Huang Z; Ren H; Chen J; Peng L; Gao F; Chen D; Wang A
Mol Ther; 2020 Oct; 28(10):2177-2190. PubMed ID: 32621798
[TBL] [Abstract][Full Text] [Related]
54. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation.
Liu J; Yue Y; Han D; Wang X; Fu Y; Zhang L; Jia G; Yu M; Lu Z; Deng X; Dai Q; Chen W; He C
Nat Chem Biol; 2014 Feb; 10(2):93-5. PubMed ID: 24316715
[TBL] [Abstract][Full Text] [Related]
55. A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity.
Buker SM; Gurard-Levin ZA; Wheeler BD; Scholle MD; Case AW; Hirsch JL; Ribich S; Copeland RA; Boriack-Sjodin PA
SLAS Discov; 2020 Apr; 25(4):361-371. PubMed ID: 31585521
[TBL] [Abstract][Full Text] [Related]
56. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
57. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
58. m
Liu P; Li F; Lin J; Fukumoto T; Nacarelli T; Hao X; Kossenkov AV; Simon MC; Zhang R
Nat Cell Biol; 2021 Apr; 23(4):355-365. PubMed ID: 33795874
[TBL] [Abstract][Full Text] [Related]
59. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
60. Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Tao Z; Zhao Y; Chen X
PeerJ; 2020; 8():e9589. PubMed ID: 32765970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
